I can see both perspectives. Gilead already and cu

I can see both perspectives. Gilead already and currently owns the HIV market and their struggles were growth (due to Hep C cure / revenues falling off drastically). Why look for growth in the market you already dominate?....Let’s buy CAR-T and get into the new hot thing in cancer. It may work out in the long term, but I think CYDY will work out much better. I held my GILD shares for awhile thinking they would buyout CYDY or license leronlimab and I wanted the upside in this paradigm shift. I have since sold all GILD and put those funds into CYDY. Our chances of 10x+ with CYDY are much better than 2x GILD IMO (even if they end up licensing HIV).

Please do your own due diligence. All my posts and comments are not to be considered investment advice.